BNTC BENITEC BIOPHARMA INC

Benitec Biopharma to Participate in the Citizens JMP Life Science Conference

Benitec Biopharma to Participate in the Citizens JMP Life Science Conference

HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that members of Benitec management will participate in Citizens JMP Life Science Conference, taking place in New York, NY from May 13-14, 2024.

Presentation Details:

Date: May 13, 2024

Time: 11:00 am EDT

Presenter: Jerel Banks, MD, PhD, Executive Chairman and Chief Executive Officer

The Benitec presentation will also be available via live webcast

Please contact your Citizens JMP representative to schedule a 1x1 meeting with Benitec management.

About Benitec Biopharma Inc.

Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at

Investor Relations Contact:

Irina Koffler

LifeSci Advisors

Tel: (917) 734-7387



EN
01/05/2024

Underlying

BNTCBENITEC BIOPHARMA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BENITEC BIOPHARMA INC

 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma Announces Updated Investor Webcast Information

Benitec Biopharma Announces Updated Investor Webcast Information -Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- -The webcast access information has been revised from the conference call information provided on October 12th- HAYWARD, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” D...

October 14, 2024 1 EN
 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma Releases Full Year 2024 Financial Results and Provid...

Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update -Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April and July- -Second Subject Dosed with the Low-Dose of BB-301 in February 2024, and Third Subject Expected to Receive the Low-Dose of BB-301 in Calendar Quarter Four of 2024- -Closed an Oversubscribed Private Placement Financing of $40.0 Million on April 22nd, Cash Runway Extended Throug...

September 26, 2024 1 EN
 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma Announces Late Breaking Oral Abstract Presentation o...

Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society HAYWARD, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that a Late Breaking Abstract on BB-301 was accepted for oral presentation at the 29th Annual Congress...

September 18, 2024 1 EN
 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar

Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar HAYWARD, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will participate in the Oculopharyngeal Muscular Dystrophy (OPMD) Awareness Day Webinar organized by the OPMD Association, on Monday, September 23, 2024 at 12 PM EST. Th...

September 17, 2024 1 EN
 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma Reports Continued Durable Improvements in the Radiog...

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study -The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the 180-day post-dose assessment following the administration of the low dose of gene therapy BB-301 as compared to the pre-dose average values reco...

July 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch